Antibody dependent cell-mediated cytotoxicity using hepatocellular carcinoma reactive monoclonal antibody

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 2, 1998, Pages 137-144

  Kuwata, Tomo ^a   Haruta, Ikuko ^a   Hasegawa, Kiyoshi ^a   Yamauchi, Katsumi ^a   Hayashi, Naoaki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Antibody dependent cellular cytotoxicity; Hepatocellular carcinoma; Tumour specific killer cells

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL CULTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

EID: 0031884399     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00628.x     Document Type: Article

References (20)

1. Komatsu T, Yamauchi K, Furukawa T, Obata H. Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers. J. Clin. Immunol. 1990; 10: 164-74.
2. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985; 313: 1485-92.
3. Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Int. J. Cancer 1991; 49: 19-24.
4. Haruta I, Yamauchi K, Aruga A et al. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: Comparison between LAK cell and CTL therapy. J. Immunother. 1996; 19: 218-23.
5. Ichino Y, Ishikawa T. Generation of human cytotoxic T lymphocytes against fresh autologous and allogenic solid tumors by mixed lymphocyte-tumor-cell culture with T cell growth factor. Auris Nasus Larynx 1985; 12 (Suppl. 2): S226-33.
6. Nitta T, Sato K, Yagita H, Okumura K. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 17: 368-71.
7. Ohzu K, Hasegawa K, Yamauchi K, Obata H. Multiplicity of newly established monoclonal antibodies against hepatocellular carcinomas. J. Gastroenterol. Hepatol. 1990; 5: 601-7.
8. Hu C, Han S, Lui W et al. Monoclonal antibodies against antigens expressed on human hepatocellular carcinoma cells. Hepatology 1986; 6: 1396-402.
9. Fuhrer JP, Xie H, Murphy MJ Jr, Ye JN, Yao Z. Characterization of a membrane-associated glycoprotein (gp43) on human hepatocellular carcinoma by a monoclonal antibody. Cancer Res. 1991; 51: 2158-63.
10. Shouval D, Eilat D, Carlson RI, Adler R, Livni N, Wands JR. Human hepatoma-associated cell surface antigen: Identification and characterization by means of monoclonal antibodies. Hepatology 1985; 5: 347-56.
11. Carlson RI, Ben-Porath E, Shouval D, Strauss W, Isselbacher KJ, Wans JR. Antigenic characterization of human hepatocellular carcinoma. J. Clin. Invest. 1985; 76: 40-51.
12. Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science 1991; 252: 1657-62.
13. Takahashi H, Nakada T, Puisieux I. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 1993; 259: 1460-3.
14. Kreitman RJ, Hansen HJ, Jones AL et al. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res. 1993; 53: 819-25.
15. Takahashi H, Nakada T, Nakaki M, Wans JR. Inhibition of hepatic metastasis of human colon cancer in nude mice by a chimeric SF-25 monoclonal antibody. Gastroenterology 1995; 108: 172-82.
16. Stepleski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl Acad. Sci. USA 85: 4852-6.
17. Sung M, Yasumura S, Johnson JT, Van Dongen GAMS, Whiteside TL. Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric antibodies reactive with human squamous-cell carcinomas of the head and neck. Int. J. Cancer 1995; 61: 864-72.
18. Goldenberg DM, Larson SM, Reisfeld RA, Schlom J. Targeting cancer with radiolabeled antibodies. Immunol. Today 1995; 16: 261-4.
19. Co MS, Queen C. Humanized antibodies for therapy. Nature 1991; 351: 501-2.
20. Bach JF, Fracchia GN, Chatenoud L. Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy. Immunol. Today 1993; 14: 421-5.